Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Jessica Kearney
 -- 2930 2023-05-17 15:43:26 |
2 format corrected.
Beatrix Zheng
 + 10 word(s) 2940 2023-05-18 03:25:50 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Kearney, J.; Gnudi, L. Therapeutic Strategies for Diabetic Kidney Disease (DKD). Encyclopedia. Available online: https://encyclopedia.pub/entry/44446 (accessed on 01 July 2024).
Kearney J, Gnudi L. Therapeutic Strategies for Diabetic Kidney Disease (DKD). Encyclopedia. Available at: https://encyclopedia.pub/entry/44446. Accessed July 01, 2024.
Kearney, Jessica, Luigi Gnudi. "Therapeutic Strategies for Diabetic Kidney Disease (DKD)" Encyclopedia, https://encyclopedia.pub/entry/44446 (accessed July 01, 2024).
Kearney, J., & Gnudi, L. (2023, May 17). Therapeutic Strategies for Diabetic Kidney Disease (DKD). In Encyclopedia. https://encyclopedia.pub/entry/44446
Kearney, Jessica and Luigi Gnudi. "Therapeutic Strategies for Diabetic Kidney Disease (DKD)." Encyclopedia. Web. 17 May, 2023.
Therapeutic Strategies for Diabetic Kidney Disease (DKD)
Edit
This entry is adapted from the peer-reviewed paper 10.3390/pharmaceutics15051343

The key approach to reduce diabetic kidney disease (DKD)-mediated end-stage renal disease (ESRD)  is to prevent and delay the renal function decline, as once a fall in renal function occurs, it is difficult to regain, apart from when normoglycemic conditions are implemented for a long time, such as following pancreas transplantation. In parallel to lifestyle, glycemic and blood pressure control, all cornerstones for the prevention of DKD, the researchers outline five major treatment “pillars” that possess major renal protective properties

diabetes kidney disease therapeutics

1. Overview

Lifestyle measures are a key component in the overall management of diabetic kidney disease (DKD). Dietary advice is important in the management of both CKD and diabetes. In CKD, the National Kidney Foundation guidelines suggest a registered dietician nutritionist’s intervention to provide nutritional advice [1]. Considerations include reducing dietary protein intake, ensuring adequate fruit and vegetables, following a Mediterranean diet, and considering the need for vitamin and mineral supplements [1]. Depending on the patient, advice to reduce potassium intake and restrict oral fluids may be given [1].
There is no specific recommended diet for diabetes, but general advice includes eating a variety of fruit and vegetables, reducing carbohydrates, saturated fats, and salts, and choosing low- over high-glycemic-index foods [2]. A very-low-calorie diet (825–853 kcal/day) has been shown to lead to remission of T2DM in almost half of patients at 12 months [3]. A very low carbohydrate diet has been shown to improve glycemic control but not renal outcomes in DKD [4]. In addition to diet, regular physical activity, not smoking and weight loss for patients with obesity are advisable in DKD [5].
In parallel to lifestyle, glycemic and blood pressure control, all cornerstones for the prevention of DKD, the researchers outline five major treatment “pillars” that possess major renal protective properties (Figure 1).
Pharmaceutics 15 01343 g001 550
Figure 1. The treatment “pillars” for renal protection in diabetes.

2. SGLT2 Inhibitors

SGLT2 inhibitors act to reduce proximal tubular glucose reabsorption from the renal glomerular filtrate [6]. SGLT2 is an energy-dependent sodium-coupled glucose transporter expressed mainly in the S1 and S2 segment of the nephron proximal tubule [7][8]. SGLT2 is upregulated in diabetes and contributes to both proximal tubule glucose and sodium reabsorption [9]. The SGLT2 inhibitors were initially developed as oral hypoglycemic agents. By reducing glucose proximal tubule reabsorption, SGLT2 inhibitors lead to an increase in urinary glucose excretion, promote weight loss of approximately 4–5 Kg, lower plasma glucose concentrations, and lead to a reduction in HbA1c of around 1.0% [10].
SGLT2 inhibitors were found to confer both cardiovascular and renal protection; clinical trials have demonstrated that SGLT2 inhibitor treatment results in a 30–40% relative risk reduction of cardiovascular death and hospitalization, which was mainly driven by reduction of heart failure [11][12][13]. The EMPAREG trial was the first to suggest a renoprotective role for the SGLT2 inhibitor empagliflozin [14]. Later, other studies such as the CANVAS and CANVAS-R showed a promising renoprotective effect of the SGLT2 antagonist canagliflozin [15]. Subsequently, a prospective study, the CREDENCE trial, enrolled patients with type 2 diabetes and albuminuria (albumin/creatinine ration 300–5000 mg/g) and chronic kidney disease (glomerular filtration rate: GFR of 30–90 mL/min/1.73 m2) that were randomized to the SGLT2 inhibitor canagliflozin at a dose of 100 mg daily or placebo. All patients were treated with RAAS inhibitors. The trial was stopped earlier due to clear benefit of patients enrolled in the treatment arm. Patient on SGLT2 inhibitor had a relative 30% reduction of a renal endpoint defined as ESRD, doubling of the serum creatinine level, or death from renal or cardiovascular causes when compared to the placebo arm [16]. Interestingly, other studies have confirmed these results in patients with T2DM and have demonstrated that the SGLT2-inhibitor-mediated renoprotective effects occurs also in the non-diabetic population [17].
The latest NICE guidelines recommend the use of SGLT2 inhibitors with metformin as dual therapy first line for patients with diabetes with established cardiovascular disease, and advise to consider their use in patients with high risk of cardiovascular disease [18]. In addition to documented weight reduction, the cardiovascular protective effects of SGLT2 inhibitors include reduction in blood pressure [19] and reduced risk of both new heart failure and of worsening existing heart failure in patients with reduced or preserved ejection fraction [11][12][13][20][21][22].
SGLT2 inhibitors, including empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin, have been observed to have beneficial renal effects in several cardiovascular outcome trials. Meta-analyses of these data have demonstrated that in diabetic patients, SGLT2 inhibitors reduce the risk of progression of renal disease, ESRD, or death from renal causes [23].
The 2022 KDIGO guidelines for diabetes management in CKD recommend the use of metformin and SGLT2 inhibitors for all patients with T2DM, CKD, and an GFR > 30 mL/min/1.73 m2 [24]. The glucose lowering effects are attenuated at GFR < 60 mL/min/1.73 m2 and minimal at GFR < 30 mL/min/1.73 m2 [25]. However, the renal and cardiovascular benefits are seen at any GFR, and guidelines advise continuing SGLT2 inhibitors even if GFR falls below 20 mL/min/1.73 m2, until renal replacement therapy is initiated [16]. The cardio-renal protective effects appear within weeks/months and seem to be independent of the improvement in glycemic control. The SGLT2 beneficial effects are likely to be driven by a hemodynamic mechanism; the main proposed mechanisms linked with renal benefits include: increased diuresis and improvement in blood pressure, tubulo-glomerular feedback leading to reduced intraglomerular pressure, increased tubular oxygenation, and reduced inflammation and fibrosis [26].

Side Effects

An initial drop in eGFR (driven by hemodynamic changes in the glomerular circulation) is seen when SGLT2 inhibitors are initiated; however, there has been no confirmed increased risk of acute kidney injury (AKI) occurrence, and conversely, they have been seen to reduce the risk of AKI in patients with T2DM [27]. Due to the increased glucosuria, SGLT2 inhibitors increase the risk of genital infections and so patients should be educated with regards to the importance of hydration and personal hygiene [28]. An increased risk of fractures and amputations has been documented, although evidence is mixed, and further evaluation is needed to confirm these associations [28]. Similarly, an association has been made with SGLT2 inhibitors and Fournier’s gangrene, but no causality has been established [28].
SGLT2 inhibitors lead to increased lipolysis and glucagonemia, and therefore, it has been recommended that they are held peri-operatively and at times of dehydration and that ketones be monitored due to the risk of ketosis in the peri-operative setting [29][30]. Healthcare professionals are advised to educate patients on the ‘sick-day rules’ when initiating SGLT2 inhibitors to enable prevention and recognition of potential ketoacidosis. If patients are unwell or unable to eat and drink as normal, they should omit the SGLT2 inhibitor and keep themselves as well hydrated as possible; patients should be informed of the symptoms of diabetic ketoacidosis and to attend Accident & Emergency department should they develop them [31]. SGLT2 inhibitors should not be restarted until eating normally for at least 24 h and never restarted if a patient develops ketoacidosis while taking them [31].

3. GLP1 Receptor Agonists

GLP1 is an incretin hormone produced in the distal small bowel and colon that triggers the release of insulin in response to oral glucose intake. Incretin hormones slow gastric emptying and increase natriuresis and diuresis [32]. Native GLP1 has a short half-life as it is cleaved by dipeptidyl-peptidase IV (DPP IV) enzymes and eliminated renally. The GLP1 receptor agonists are synthetized from either exendin-4 from the saliva of the Gila monster, a species of venomous lizard, or human GLP1 analogues, both of which are resistant to the DPP IV degradation. The exendin-4 based agents, such as exenatide and lixisenatide, have a short half-life but strongly inhibit gastric emptying and cause a greater reduction in post-prandial hyperglycemia [33].
GLP1 receptor agonists are a group of drugs used to treat T2DM and lead to a reduction in HbA1c. GLP1 receptors are present in many tissues, but with regards to the therapeutic effects on diabetes, their activation is thought to increase insulin secretion, and reduce beta cell apoptosis and glucagon release in a glucose-dependent way [32]. Furthermore, GLP1 receptor agonists bind the GLP1 receptor present in the central nervous system and the gastrointestinal tract and favor weight loss in obese patients through an increase in satiety, reducing appetite, delaying gastric emptying, and potentially increasing thermogenesis of brown adipose tissue [34][35].
Data from clinical trials suggest that GLP1 receptor agonists improve surrogate renal endpoints, plausibly beyond the effects of improved glycemic control [36]. Exendin-4-based GLP1 receptor agonists are renally excreted and so their use is contraindicated at an eGFR < 30 mL/min/1.73 m2 [37]. Meanwhile, the human GLP1 receptor agonists dulaglutide, semaglutide, and liraglutide are longer-acting and are more effective at reducing fasting blood sugar and HbA1C [38]. They are not eliminated by the kidneys and so can be safely used down to an eGFR of 15 mL/min/1.73 m2 [37].
Cardiovascular outcome trials have shown that GLP1 receptor agonists are efficacious in reducing the risk of cardiovascular events (stroke, myocardial infarction, or cardiovascular death) in patients with T2DM [39]. The same trials have shown that GLP1 receptor agonists prevent worsening of renal function in patients with T2DM. This was measured as a composite outcome of ≥40% decline in eGFR or doubling of creatinine, need for renal replacement therapy, new macroalbuminuria, or death from renal disease [39]. The FLOW trial will be the first dedicated kidney outcome trial to evaluate whether the GLP1 receptor agonist semaglutide delays progression of kidney disease and reduces the risk of death from renal or cardiovascular disease in patients with T2DM and CKD (ClinicalTrials.gov Identifier: NCT03819153). Data are lacking on patients with ESRD on hemodialysis or renal transplant patients.
Clinical trials on DPP IV inhibitors, which prevent GLP1 degradation, have not shown a cardiovascular benefit for patients with T2DM [40]. The reasons behind this observation are unknown but could relate to the "physiological" concentration of circulating GLP1 achieved in patients treated with DPP IV inhibitors versus the "supraphysiological" levels observed with GLP-1 receptor agonists [41].
Not only do GLP1 receptor agonists improve glycemic control and stimulate weight loss, but evidence suggests they also confer nephroprotection via interaction with the renal cells, with GLP1 receptors thought to be present in the kidney [37]. The proposed mechanisms of renal protection include a reduction in oxidative stress, fibrosis, inflammation, and possibly increased natriuresis [42]. Guidelines (KDIGO) advise the use of GLP1 receptor agonists in patients with T2DM and CKD who have not achieved glycemic targets with metformin and SGLT2 inhibitors [24].

Side Effects

GLP1 receptor agonists do not cause hypoglycemia; however, if a patient is already on insulin or a sulphonylurea, the doses of these may need to be reduced to avoid hypoglycemia [43]. The most common side effects of GLP1 receptor agonists are gastrointestinal such as nausea, vomiting, reflux, diarrhea, or constipation [43][44]. Proposed methods of managing these include educating patients, escalating dosing more slowly if indicated, increasing hydration, reducing portion size, and considering switching to an alternative GLP1 receptor agonist [44]. Associations have been made between GLP1 receptor agonists and pancreatitis, pancreatic cancer or thyroid cancer; however, current evidence does not support a causative link [34].

4. Non-Steroidal Mineralocorticoid Receptor Antagonists

Activation of mineralocorticoid receptors leads to inflammation and fibrosis contributing to progression of CKD and cardiovascular dysfunction [30]. While recommended, the use of steroidal mineralocorticoid receptor antagonists (MRA) for patients with CKD and heart failure is often limited due to concerns of hyperkalemia, gynecomastia, impotence, and menstrual disturbances. Finerenone is a non-steroidal, selective MRA with low affinity for androgen, glucocorticoid, progesterone, and estrogen receptors and high selectivity for mineralocorticoid receptors [45][46]. It said to be more effective at reducing the pathological processes contributing to CKD than steroidal MRAs, with theoretically lower side effects [47].
Finerenone binds similarly to its receptor both in the heart and kidney when compared to the steroidal MRA spironolactone, which is preferentially distributed in the kidneys. Compared with eplerenone, another steroidal MRA, finerenone holds more potent anti-inflammatory and anti-fibrotic effects on the heart and kidney in experimental animal models. Non-steroidal MRAs have a better benefit–risk ratio than steroidal MRAs, with a reduced risk for hyperkalemia [47].
In two major phase 3 trials, FIDELIO-DKD and FIGARO-DKD, conducted in patients with T2DM and chronic kidney disease, finerenone treatment on top of maximally tolerated RAAS inhibitor treatment was shown to confer both renoprotection (composite of >40% reduction in eGFR, kidney failure, or death from renal cause) and cardioprotection (composite of cardiovascular death, non-fatal myocardial infarction or stroke, hospitalization for heart failure) [48][49]. In FIDELIO-DKD, patients either had a urine albumin–creatinine ratio (UACR) of 30–300 mg/g with an GFR of 25–60 mL/min/1.73 m2 of body surface area as well as diabetic retinopathy or a UACR of 300–5000 mg/g with an GFR of at least 25–75 mL/min/1.73 m2 [48]. The inclusion criteria of FIGARO-DKD were similar, with patients either having a UACR of 30–300 mg/g with an GFR of 25–90 mL/min/1.73 m2 or a UACR of 300–5000 mg/g with an GFR of at least 60 mL/min/1.73 m2 [49]. Patients with symptomatic heart failure with reduced ejection fraction were not eligible for inclusion in these trials.
The results of these two trials were combined in the pre-specified FIDELITY analysis, which confirmed the clinical cardiac [hazard ratio (HR): 0.86, 95% confidence interval (CI): 0.78, 0.95] and renal (HR: 0.77, 95% CI: 0.67, 0.88) protective properties of finerenone [50]. Cardio- and renaoprotective effects seemed independent of change in blood pressure as finerenone conferred only a modest effect on blood pressure [48][49][50].

Side Effects

A meta-analysis of the use of finerenone (when used in combination with another RAAS blockade agent) demonstrated an increased incidence of hyperkalemia compared with placebo but lower than with spironolactone. The increase in potassium plasma levels observed was moderate at only 0.17 mmol/L; however, potassium monitoring is advised [45]. NICE guidelines state finerenone should not be initiated at an eGFR of <25 mL/min/1.73 m2 and it should be discontinued if GFR < 25 mL/min/1.73 m2 [37]. Other listed side-effects are hypotension and pruritus [51].

5. RAAS Inhibitors

The RAAS is central to blood pressure regulation and fluid and electrolyte balance. RAAS inhibition with angiotensin-converting enzyme inhibitors (ACEis) and angiotensin-2 receptor blockers (ARBs) reduces the activity of angiotensin and thereby leads to vasodilation, reduced sympathetic adrenergic activity, increased natriuresis and diuresis, and inhibition of cardiac and vascular remodeling. Blood pressure control is effective against the progression of DKD [52] and ACEis and ARBs are the first-line treatment for patients with DKD [52]. RAAS blockade has been shown reduce albuminuria and to be renoprotective for this patient group [53]. The benefits to renal function that these medications provide exceed that attributable to blood pressure lowering [53]. However, double RAAS blockade with ACEis/ARBs has been associated with an increased risk of acute kidney injury and hyperkalemia [54]. In patients with T2DM on ACEIs, ARBs, or combination treatment, the addition of a mineralocorticoid antagonist results in ~50% reduction in albuminuria [55] and retains the renoprotective effect [48][56][57].

Side Effects

Adverse effects of ACEis and ARBs include hyperkalemia, renal impairment, angio-edema, and dizziness; a cough can also occur with ACEis [58]. Use of ACEis or ARBs in patients with low renal function (CKD4–5), or combination of a mineralocorticoid antagonist with ACEis or ARBs therapy, can often increase plasma potassium or result in AKI. When starting an ACEis, or increasing the dose, it is advised to check renal function and electrolytes 1–2 weeks later, with dose adjustment or medication cessation being considered if the GFR decreases by >25%, creatinine increases by >30%, or serum potassium is >5 mmol/L [58]. Patients with conditions such as CKD stage 4–5 or heart failure are at higher risk of hyperkalemia [59]. Clinicians should conduct a careful risk–benefit assessment for those patients whom double RAAS blockade is to be considered [60].

6. Statins 

An inverse relationship exists between GFR and cardiovascular disease, with cardiovascular disease being the predominant cause of increased mortality in patients with CKD [61]. Renal dysfunction alters the composition of lipids to a more atherogenic profile; hypertriglyceridemia, reduced HDL cholesterol, and variable LDL and total cholesterol are seen [62]. Dyslipidemia per se is also a recognized risk for CKD and its progression [63]. Association of British Clinical Diabetologist and UK Renal Association guidelines recommend annual lipid profiles for patients with DKD [64].

Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors that act to disrupt the liver’s production of cholesterol. NICE guidelines state that adults with CKD should be offered a statin to reduce their risk of cardiovascular events [8]. A renoprotective effect of statins, independent from cholesterol lowering, has also been postulated and a reduction inmicroalbuminuria has been observed [101–105]. Atorvastatin has been seen to reduce cardiovascular disease by 42% in those with GFR 30–60 mL/min/1.73 m2 [106]. The Association of British Clinical Diabetologist and UK Renal Association suggest the use of a statin in patients with DKD and that treatment targets should be a total cholesterol of 4 mmol/L, non-HDL cholesterol  2.5 mmol/L, and LDL cholesterol to  2 mmol/L [100].

Side-Effects

Listed side-effects of statins include myalgia, gastrointestinal symptoms, hyperglycemia, nasopharyngitis, headache, and hepatotoxicity [65]. NICE guidelines advise measuring liver function tests at 3 and 12 months after initiation of treatment. Many statins are metabolized renally and so their doses should be reduced at lower creatinine clearance levels. Statin use can cause myopathy and rhabdomyolysis that can lead to their discontinuation; however, the rates of these adverse effects are low (1.6 cases per 100,000 person years and 5 cases per 100,000 person years, respectively) [66]. If symptoms of myalgia or cramps occur then creatinine kinase levels should be measured, and if they are >5 times the upper limit of normal, then a statin should be held [65].

Conclusion 

The fight against diabetic kidney disease is centred on the prevention of its development and progression. In recent years, significant new tools have become available to prevent and treat DKD. Prevention requires aggressive treatment and close follow up of patients with diabetes. Early intervention will improve patients' health outcomes, quality of life, and health- and society-related costs. Studies aimed at better understanding the mechanisms of these new molecules may open new opportunities for patient's personalized treatments and for the development of new therapeutic targets. 

References

  1. Ikizler, T.A.; Burrowes, J.D.; Byham-Gray, L.D.; Campbell, K.L.; Carrero, J.J.; Chan, W.; Fouque, D.; Friedman, A.N.; Ghaddar, S.; Goldstein-Fuchs, D.J.; et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am. J. Kidney Dis. 2020, 76, S1–S107.
  2. Crapo, P.A. Simple versus complex carbohydrate use in the diabetic diet. Annu. Rev. Nutr. 1985, 5, 95–114.
  3. Lean, M.E.; Leslie, W.S.; Barnes, A.C.; Brosnahan, N.; Thom, G.; McCombie, L.; Peters, C.; Zhyzhneuskaya, S.; Al-Mrabeh, A.; Hollingsworth, K.G.; et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): An open-label, cluster-randomised trial. Lancet 2018, 391, 541–551.
  4. Zainordin, N.A.; Eddy Warman, N.A.; Mohamad, A.F.; Abu Yazid, F.A.; Ismail, N.H.; Chen, X.W.; Koshy, M.; Abdul Rahman, T.H.; Mohd Ismail, N.; Abdul Ghani, R. Safety and efficacy of very low carbohydrate diet in patients with diabetic kidney disease-A randomized controlled trial. PLoS ONE 2021, 16, e0258507.
  5. Onyenwenyi, C.; Ricardo, A.C. Impact of Lifestyle Modification on Diabetic Kidney Disease. Curr. Diabetes Rep. 2015, 15, 60.
  6. Wright, E.M.; Loo, D.D.; Hirayama, B.A. Biology of human sodium glucose transporters. Physiol. Rev. 2011, 91, 733–794.
  7. Solini, A. Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Acta Diabetol. 2016, 53, 863–870.
  8. Ferrannini, E.; Solini, A. SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat. Rev. Endocrinol. 2012, 8, 495–502.
  9. Rahmoune, H.; Thompson, P.W.; Ward, J.M.; Smith, C.D.; Hong, G.; Brown, J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54, 3427–3434.
  10. Fonseca-Correa, J.I.; Correa-Rotter, R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front. Med. 2021, 8, 777861.
  11. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373, 2117–2128.
  12. Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R.; et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017, 377, 644–657.
  13. Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2019, 380, 347–357.
  14. Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B.; et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 323–334.
  15. Perkovic, V.; de Zeeuw, D.; Mahaffey, K.W.; Fulcher, G.; Erondu, N.; Shaw, W.; Barrett, T.D.; Weidner-Wells, M.; Deng, H.; Matthews, D.R.; et al. Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018, 6, 691–704.
  16. Perkovic, V.; Jardine, M.J.; Neal, B.; Bompoint, S.; Heerspink, H.J.L.; Charytan, D.M.; Edwards, R.; Agarwal, R.; Bakris, G.; Bull, S.; et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N. Engl. J. Med. 2019, 380, 2295–2306.
  17. Heerspink, H.J.L.; Stefansson, B.V.; Correa-Rotter, R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.E.; McMurray, J.J.V.; Lindberg, M.; Rossing, P.; et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383, 1436–1446.
  18. National Institute for Health and Care Excellence. Diabetes-Type 2. 2023. Available online: https://cks.nice.org.uk/topics/diabetes-type-2/management/management-adults (accessed on 20 April 2023).
  19. Georgianos, P.I.; Agarwal, R. Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation with Low-Dose Hydrochlorothiazide. Diabetes Care 2019, 42, 693–700.
  20. McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Kober, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Belohlavek, J.; et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N. Engl. J. Med. 2019, 381, 1995–2008.
  21. Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Bohm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N. Engl. J. Med. 2021, 385, 1451–1461.
  22. Solomon, S.D.; McMurray, J.J.V.; Claggett, B.; de Boer, R.A.; DeMets, D.; Hernandez, A.F.; Inzucchi, S.E.; Kosiborod, M.N.; Lam, C.S.P.; Martinez, F.; et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N. Engl. J. Med. 2022, 387, 1089–1098.
  23. Lo, K.B.; Gul, F.; Ram, P.; Kluger, A.Y.; Tecson, K.M.; McCullough, P.A.; Rangaswami, J. The Effects of SGLT2 Inhibitors on Cardiovascular and Renal Outcomes in Diabetic Patients: A Systematic Review and Meta-Analysis. Cardiorenal Med. 2020, 10, 1–10.
  24. Rossing, P.; Caramori, M.L.; Chan, J.C.N.; Heerspink, H.J.L.; Hurst, C.; Khunti, K.; Liew, A.; Michos, E.D.; Navaneethan, S.D.; Olowu, W.A.; et al. Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: An update based on rapidly emerging new evidence. Kidney Int. 2022, 102, 990–999.
  25. Cherney, D.Z.I.; Cooper, M.E.; Tikkanen, I.; Pfarr, E.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Lund, S.S. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int. 2018, 93, 231–244.
  26. Vallon, V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 2015, 66, 255–270.
  27. Bailey, C.J.; Day, C.; Bellary, S. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease. Curr. Diabetes Rep. 2022, 22, 39–52.
  28. Garofalo, C.; Borrelli, S.; Liberti, M.E.; Andreucci, M.; Conte, G.; Minutolo, R.; Provenzano, M.; De Nicola, L. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Medicina 2019, 55, 268.
  29. Musso, G.; Saba, F.; Cassader, M.; Gambino, R. Diabetic ketoacidosis with SGLT2 inhibitors. BMJ 2020, 371, m4147.
  30. Medicines and Healthcare Products Regulatory Agency. Drug Safety Update. 2020. Available online: https://www.gov.uk/drug-safety-update/sglt2-inhibitors-monitor-ketones-in-blood-during-treatment-interruption-for-surgical-procedures-or-acute-serious-medical-illness (accessed on 20 April 2023).
  31. Dashora, U.; Gregory, R.; Winocour, P.; Dhatariya, K.; Rowles, S.; Macklin, A.; Rayman, G.; Nagi, D.; Whitehead, K.; Beba, H.; et al. Association of British Clinical Diabetologists (ABCD) and Diabetes UK joInt. position statement and recommendations for non-diabetes specialists on the use of sodium glucose co-transporter 2 inhibitors in people with type 2 diabetes (January 2021). Clin. Med. 2021, 21, 204–210.
  32. Yu, J.H.; Park, S.Y.; Lee, D.Y.; Kim, N.H.; Seo, J.A. GLP-1 receptor agonists in diabetic kidney disease: Current evidence and future directions. Kidney Res. Clin. Pract. 2022, 41, 136–149.
  33. Meier, J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2012, 8, 728–742.
  34. Zhao, X.; Wang, M.; Wen, Z.; Lu, Z.; Cui, L.; Fu, C.; Xue, H.; Liu, Y.; Zhang, Y. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Front. Endocrinol. 2021, 12, 721135.
  35. Nauck, M.A.; Quast, D.R.; Wefers, J.; Meier, J.J. GLP-1 receptor agonists in the treatment of type 2 diabetes—State-of-the-art. Mol. Metab. 2021, 46, 101102.
  36. Kristensen, S.L.; Rorth, R.; Jhund, P.S.; Docherty, K.F.; Sattar, N.; Preiss, D.; Kober, L.; Petrie, M.C.; McMurray, J.J.V. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019, 7, 776–785.
  37. Granata, A.; Maccarrone, R.; Anzaldi, M.; Leonardi, G.; Pesce, F.; Amico, F.; Gesualdo, L.; Corrao, S. GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: State of the art. Clin. Kidney J. 2022, 15, 1657–1665.
  38. Buse, J.B.; Nauck, M.; Forst, T.; Sheu, W.H.; Shenouda, S.K.; Heilmann, C.R.; Hoogwerf, B.J.; Gao, A.; Boardman, M.K.; Fineman, M.; et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): A randomised, open-label study. Lancet 2013, 381, 117–124.
  39. Sattar, N.; Lee, M.M.Y.; Kristensen, S.L.; Branch, K.R.H.; Del Prato, S.; Khurmi, N.S.; Lam, C.S.P.; Lopes, R.D.; McMurray, J.J.V.; Pratley, R.E.; et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9, 653–662.
  40. Patoulias, D.I.; Boulmpou, A.; Teperikidis, E.; Katsimardou, A.; Siskos, F.; Doumas, M.; Papadopoulos, C.E.; Vassilikos, V. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World J. Cardiol. 2021, 13, 585–592.
  41. Brunton, S. GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: Is one approach more successful or preferable than the other? Int. J. Clin. Pract. 2014, 68, 557–567.
  42. Kawanami, D.; Takashi, Y. GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Front. Pharmacol. 2020, 11, 967.
  43. Wharton, S.; Davies, M.; Dicker, D.; Lingvay, I.; Mosenzon, O.; Rubino, D.M.; Pedersen, S.D. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: Recommendations for clinical practice. Postgrad. Med. 2022, 134, 14–19.
  44. Filippatos, T.D.; Panagiotopoulou, T.V.; Elisaf, M.S. Adverse Effects of GLP-1 Receptor Agonists. Rev. Diabet. Stud. 2014, 11, 202–230.
  45. Zhang, M.Z.; Bao, W.; Zheng, Q.Y.; Wang, Y.H.; Sun, L.Y. Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front. Pharmacol. 2022, 13, 819327.
  46. Bakris, G.; Filippatos, G.S.; Farmakis, D.; Epstein, M.; Pitt, B. Aldosterone Antagonists and CVD. 2021. Available online: https://www.acc.org/latest-in-cardiology/articles/2021/07/19/13/42/aldosterone-antagonists-and-cvd (accessed on 20 April 2023).
  47. Agarwal, R.; Kolkhof, P.; Bakris, G.; Bauersachs, J.; Haller, H.; Wada, T.; Zannad, F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur. Heart J. 2021, 42, 152–161.
  48. Bakris, G.L.; Agarwal, R.; Anker, S.D.; Pitt, B.; Ruilope, L.M.; Rossing, P.; Kolkhof, P.; Nowack, C.; Schloemer, P.; Joseph, A.; et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2020, 383, 2219–2229.
  49. Pitt, B.; Filippatos, G.; Agarwal, R.; Anker, S.D.; Bakris, G.L.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Schloemer, P.; et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N. Engl. J. Med. 2021, 385, 2252–2263.
  50. Agarwal, R.; Filippatos, G.; Pitt, B.; Anker, S.D.; Rossing, P.; Joseph, A.; Kolkhof, P.; Nowack, C.; Gebel, M.; Ruilope, L.M.; et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur. Heart J. 2022, 43, 474–484.
  51. National Institute for Health and Care Excellence. British National Formulary. Finerenone. 2022. Available online: https://bnf.nice.org.uk/drugs/finerenone (accessed on 20 April 2023).
  52. Gnudi, L.; Gentile, G.; Ruggenenti, P. The patient with diabetes mellitus. In Oxford Textbook of Clinical Nephrology; Turner, N., Lamiere, N., Goldsmith, D.J., Wineearls, C.G., Himmelfarb, J., Remuzzi, G., Eds.; Oxford University Press: Oxford, UK, 2016; Volume 2, pp. 1199–1247.
  53. Lewis, E.J.; Hunsicker, L.G.; Bain, R.P.; Rohde, R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 1993, 329, 1456–1462.
  54. Fried, L.F.; Emanuele, N.; Zhang, J.H.; Brophy, M.; Conner, T.A.; Duckworth, W.; Leehey, D.J.; McCullough, P.A.; O’Connor, T.; Palevsky, P.M.; et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N. Engl. J. Med. 2013, 369, 1892–1903.
  55. Navaneethan, S.D.; Nigwekar, S.U.; Sehgal, A.R.; Strippoli, G.F. Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 2009, 4, 542–551.
  56. Bianchi, S.; Bigazzi, R.; Campese, V.M. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006, 70, 2116–2123.
  57. Van den Meiracker, A.H.; Baggen, R.G.; Pauli, S.; Lindemans, A.; Vulto, A.G.; Poldermans, D.; Boomsma, F. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J. Hypertens. 2006, 24, 2285–2292.
  58. National Institute for Health and Care Excellence. Angiotensin-Convertine Enzyme Inhibitors. 2022. Available online: https://cks.nice.org.uk/topics/hypertension/prescribing-information/angiotensin-converting-enzyme-inhibitors (accessed on 20 April 2023).
  59. Khosla, N.; Kalaitzidis, R.; Bakris, G.L. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am. J. Nephrol. 2009, 30, 418–424.
  60. Weir, M.R.; Rolfe, M. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors. Clin. J. Am. Soc. Nephrol. 2010, 5, 531–548.
  61. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351, 1296–1305.
  62. Visconti, L.; Benvenga, S.; Lacquaniti, A.; Cernaro, V.; Bruzzese, A.; Conti, G.; Buemi, M.; Santoro, D. Lipid disorders in patients with renal failure: Role in cardiovascular events and progression of chronic kidney disease. J. Clin. Transl. Endocrinol. 2016, 6, 8–14.
  63. Schaeffner, E.S.; Kurth, T.; Curhan, G.C.; Glynn, R.J.; Rexrode, K.M.; Baigent, C.; Buring, J.E.; Gaziano, J.M. Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 2003, 14, 2084–2091.
  64. Zac-Varghese, S.; Mark, P.; Winocour, P.; Association of British Clinical Diabetologist and UK Renal Association. Clinical Practice Guidelines for Management of Lipids in Adults with Diabetic Kidney Disease. 2021. Available online: https://abcd.care/sites/abcd.care/files/site_uploads/Resources/Position-Papers/Management-of-lipids-in%20adults-with-DKD.pdf (accessed on 20 April 2023).
  65. National Institute for Health and Care Excellence. Lipid Modification and Cardiovascular Disease Prevention. 2023. Available online: https://cks.nice.org.uk/topics/lipid-modification-cvd-prevention (accessed on 20 April 2023).
  66. Ezad, S.; Cheema, H.; Collins, N. Statin-induced rhabdomyolysis: A complication of a commonly overlooked drug interaction. Oxf. Med. Case Rep. 2018, 2018, omx104.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medicine, General & Internal
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Jessica Kearney
,
Luigi Gnudi
View Times: 232
Revisions: 2 times (View History)
Update Date: 18 May 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback